Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Putnam Biorevolution ETF (SYNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: SYNB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 2.45% | Avg. Invested days 59 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Volume (30-day avg) - | Beta - | 52 Weeks Range 24.57 - 33.00 | Updated Date 06/29/2025 |
52 Weeks Range 24.57 - 33.00 | Updated Date 06/29/2025 |
Upturn AI SWOT
Putnam Biorevolution ETF
ETF Overview
Overview
The Putnam BioRevolution ETF (SYNB) seeks long-term capital appreciation by investing in companies that are leaders, enablers, or beneficiaries of the BioRevolution u2013 a convergence of advancements in biology, technology, and engineering that could transform multiple industries.
Reputation and Reliability
Putnam Investments is a well-established asset management firm with a long history in the financial industry. It is generally regarded as reputable and reliable.
Management Expertise
Putnam has a dedicated team of investment professionals with experience in the healthcare and biotechnology sectors.
Investment Objective
Goal
To seek long-term capital appreciation by investing in companies involved in the BioRevolution.
Investment Approach and Strategy
Strategy: The ETF does not track a specific index. It uses an active management strategy focused on identifying companies that are leaders, enablers, or beneficiaries of the BioRevolution.
Composition The ETF primarily holds stocks of companies in the healthcare, biotechnology, and related sectors.
Market Position
Market Share: Data not available to provide a specific market share.
Total Net Assets (AUM): 69698318
Competitors
Key Competitors
- ARK Genomic Revolution ETF (ARKG)
- Global X Genomics & Biotechnology ETF (GNOM)
- iShares Biotechnology ETF (IBB)
Competitive Landscape
The competitive landscape is defined by other genomics and biotechnology ETFs. SYNB's active management approach differentiates it, though this can result in higher fees and potentially increased volatility compared to passively managed ETFs. ARKG has a larger AUM and first mover advantage. GNOM is more diversified.
Financial Performance
Historical Performance: Historical performance data is not available in this JSON format.
Benchmark Comparison: Benchmark comparison data is not available in this JSON format.
Expense Ratio: 0.0068
Liquidity
Average Trading Volume
SYNB exhibits a moderate average trading volume, which may impact the ease of buying or selling shares.
Bid-Ask Spread
The bid-ask spread fluctuates based on market conditions and trading volume, influencing the cost of trading the ETF.
Market Dynamics
Market Environment Factors
Economic indicators, healthcare spending, and regulatory changes in the biotechnology and healthcare sectors affect SYNB. Innovation in genomics, synthetic biology, and related fields also influence the fund.
Growth Trajectory
Growth trends are tied to the advancement of BioRevolution technologies and increasing investment in these fields. Changes to strategy and holdings are determined by the fund's active management.
Moat and Competitive Advantages
Competitive Edge
SYNB's advantage lies in its active management approach, which allows for strategic allocation to companies involved in the BioRevolution. Its focused approach on a niche market segment gives it the potential to outperform broader biotechnology ETFs. The fund's management team has expertise in identifying and investing in companies driving innovation within the BioRevolution. This provides investors access to companies shaping the future of medicine, agriculture and industrial processing.
Risk Analysis
Volatility
SYNB's volatility is subject to the overall market, however sector-specific and concentrated portfolios can lead to higher levels of volatility.
Market Risk
The fund's underlying assets are subject to market risk associated with the biotechnology and healthcare sectors, including regulatory approvals, clinical trial outcomes, and competitive pressures.
Investor Profile
Ideal Investor Profile
The ideal investor is someone with a high risk tolerance interested in the long-term growth potential of the BioRevolution.
Market Risk
SYNB is suitable for long-term investors seeking exposure to innovative companies in the biotechnology and healthcare sectors.
Summary
Putnam BioRevolution ETF is an actively managed fund focused on companies benefiting from advancements in biology, technology, and engineering. The ETF offers targeted exposure to the BioRevolution, potentially outperforming broad biotechnology ETFs. Its active management provides flexibility but also results in a higher expense ratio. This fund is suitable for investors with high risk tolerance, seeking long-term capital appreciation.
Similar ETFs
Sources and Disclaimers
Data Sources:
- Putnam Investments website
- ETF.com
- Morningstar
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be made based on your own research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Putnam Biorevolution ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.